We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BioFire Diagnostics

BioFire Diagnostics, a subsidiary of bioMérieux SA, offers easy-to-use clinical molecular diagnostic solutions based ... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Testing Analyzed in Suspected Meningitis Diagnosis

By LabMedica International staff writers
Posted on 07 Dec 2021
Bacterial meningitis is a potentially fatal infection of the central nervous system (CNS) that is associated with significant complications including neurologic deficits and epilepsy in the majority of survivors.

Rapid diagnosis and treatment are critical to reducing morbidity and mortality; however, evaluation of suspected meningitis is complex and challenging due to its nonspecific presentation, the limited diagnostic utility of the clinical exam, and the requirement of cerebrospinal fluid (CSF) testing for diagnosis, which traditionally has long turnaround times for culture results and can be affected by antibiotic therapy initiated before performing lumbar puncture.

Medical Doctors at Weill Cornell Medicine (New York, NY, USA) performed a retrospective pre-post intervention study that included adults ≥18 years of age who presented to the emergency department with suspected bacterial meningitis defined by the following criteria: (1) received empiric antibiotic therapy for bacterial meningitis; (2) had lumbar puncture performed in the emergency department; and (3) underwent microbiological testing with CSF culture in the preintervention period and multiplex PCR ME panel testing plus CSF culture in the postintervention period.

The team analyzed the use of the FilmArray meningitis/encephalitis (ME) panel (BioFire Diagnostics, LLC, Salt Lake City, UT, USA), which has been US Food and Drug Administration-approved for use in community-acquired CNS infections, has permitted rapid identification (within 1 hour) of 14 different viral, bacterial, and fungal agents associated with ME in CSF using a multiplex polymerase chain reaction (PCR) system. More...
The scientists gathered data from annual chart reviews over a 3-year period before and after implementation of the ME multiplex PCR panel on February 14, 2017. There were 137 patients in the pre-panel period and 69 patients in the post-panel period.

The investigators reported that the positive detection rate of bacterial pathogens was 3/137 (2.2%) by CSF culture in the pre-multiplex PCR ME panel period and 3/69 (4.3%) by the multiplex PCR ME panel in the post-multiplex PCR ME panel period. There was no difference in the proportion of patients for whom any pathogen was detected by microbiological testing between pre- and post-multiplex PCR ME panel periods (17.5% versus 20.3%). They found that once the panel was implemented, 46% more patients had empiric antibiotic therapy discontinued or de-escalated compared with before the panel was used.

Among 14 patients in the post-multiplex PCR ME panel period for whom a pathogen was identified, three patients had therapy targeted to bacterial pathogens (two S. pneumoniae, one H. influenzae) and 11 to viral pathogens (five enterovirus, three herpes simplex virus 2, three varicella zoster virus). The average turnaround time for the multiplex PCR ME panel was 2.6 hours. In the pre-multiplex PCR ME panel period, the average turnaround time for viral pathogen testing (performed by a viral encephalitis PCR panel on CSF samples) was 71.3 hours.

The authors concluded that implementation of a multiplex PCR ME panel for testing of adult patients who present to the emergency department with suspected bacterial meningitis appears to reduce the duration of empiric antibiotic therapy, time to targeted therapy, and possibly hospital length of stay compared with traditional microbiological testing methods. The study was published in the October, 2021 issue of the journal Open Forum Infectious Diseases.

Related Links:
Weill Cornell Medicine
BioFire Diagnostics



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.